Found: 52
Select item for more details and to access through your institution.
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 2, p. N.PAG, doi. 10.3390/jpm12020128
- By:
- Publication type:
- Article
Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New Results.
- Published in:
- Journal of Personalized Medicine, 2021, v. 11, n. 3, p. 206, doi. 10.3390/jpm11030206
- By:
- Publication type:
- Article
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2021, v. 40, n. 1, p. 1, doi. 10.1186/s13046-020-01811-8
- By:
- Publication type:
- Article
The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 7, p. 3871, doi. 10.3390/ijms23073871
- By:
- Publication type:
- Article
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 2, p. 820, doi. 10.3390/ijms23020820
- By:
- Publication type:
- Article
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 3, p. 1166, doi. 10.3390/ijms22031166
- By:
- Publication type:
- Article
Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities.
- Published in:
- Vaccines, 2021, v. 9, n. 6, p. 623, doi. 10.3390/vaccines9060623
- By:
- Publication type:
- Article
The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer.
- Published in:
- Life (2075-1729), 2022, v. 12, n. 10, p. 1552, doi. 10.3390/life12101552
- By:
- Publication type:
- Article
Cutaneous Metastasis from Colorectal Cancer: Making Light on an Unusual and Misdiagnosed Event.
- Published in:
- Life (2075-1729), 2021, v. 11, n. 9, p. 954, doi. 10.3390/life11090954
- By:
- Publication type:
- Article
Editorial: Optimizing the first-line treatment for metastatic colorectal cancer.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1366383
- By:
- Publication type:
- Article
Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1187623
- By:
- Publication type:
- Article
Letter: be careful of gastrointestinal CMV infection in adverse events from ICIs therapy in solid tumours.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 8, p. 916, doi. 10.1111/apt.17416
- By:
- Publication type:
- Article
Circulating tumor DNA in patients with locally advanced rectal cancer treated with multimodal treatment.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241249602
- By:
- Publication type:
- Article
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221096878
- By:
- Publication type:
- Article
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2019, v. 38, n. 1, p. N.PAG, doi. 10.1186/s13046-019-1230-z
- By:
- Publication type:
- Article
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2019, v. 38, n. 1, p. N.PAG, doi. 10.1186/s13046-019-1035-0
- By:
- Publication type:
- Article
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
- Published in:
- 2022
- By:
- Publication type:
- journal article
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/1758835921992974
- By:
- Publication type:
- Article
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/1758835921992974
- By:
- Publication type:
- Article
Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835920936089
- By:
- Publication type:
- Article
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations.
- Published in:
- Therapeutic Advances in Medical Oncology, 2020, v. 12, p. 1, doi. 10.1177/1758835920925219
- By:
- Publication type:
- Article
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials.
- Published in:
- Cancers, 2023, v. 15, n. 7, p. 2117, doi. 10.3390/cancers15072117
- By:
- Publication type:
- Article
Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review.
- Published in:
- Cancers, 2022, v. 14, n. 23, p. 5955, doi. 10.3390/cancers14235955
- By:
- Publication type:
- Article
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13 , 1941.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR.
- Published in:
- Cancers, 2022, v. 14, n. 13, p. N.PAG, doi. 10.3390/cancers14133053
- By:
- Publication type:
- Article
Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy.
- Published in:
- Cancers, 2021, v. 13, n. 22, p. 5715, doi. 10.3390/cancers13225715
- By:
- Publication type:
- Article
How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma.
- Published in:
- Cancers, 2021, v. 13, n. 18, p. 4719, doi. 10.3390/cancers13184719
- By:
- Publication type:
- Article
Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer.
- Published in:
- Cancers, 2021, v. 13, n. 8, p. 1941, doi. 10.3390/cancers13081941
- By:
- Publication type:
- Article
Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience.
- Published in:
- Cancers, 2019, v. 11, n. 10, p. 1504, doi. 10.3390/cancers11101504
- By:
- Publication type:
- Article
Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells.
- Published in:
- Cancers, 2019, v. 11, n. 10, p. 1430, doi. 10.3390/cancers11101430
- By:
- Publication type:
- Article
Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines.
- Published in:
- Translational Medicine Communications, 2023, v. 8, n. 1, p. 1, doi. 10.1186/s41231-022-00133-5
- By:
- Publication type:
- Article
Comparison of Anti–Programmed Cell Death Ligand 1 Therapy Combinations vs Sunitinib for Metastatic Renal Cell Carcinoma: A Meta-analysis.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 5, p. e2314144, doi. 10.1001/jamanetworkopen.2023.14144
- By:
- Publication type:
- Article
Mucosal Microbiota from Colorectal Cancer, Adenoma and Normal Epithelium Reveals the Imprint of Fusobacterium nucleatum in Cancerogenesis.
- Published in:
- Microorganisms, 2023, v. 11, n. 5, p. 1147, doi. 10.3390/microorganisms11051147
- By:
- Publication type:
- Article
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial.
- Published in:
- International Journal of Cancer, 2023, v. 153, n. 8, p. 1520, doi. 10.1002/ijc.34632
- By:
- Publication type:
- Article
Real‐world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions.
- Published in:
- International Journal of Cancer, 2023, v. 153, n. 1, p. 133, doi. 10.1002/ijc.34462
- By:
- Publication type:
- Article
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.
- Published in:
- International Journal of Cancer, 2022, v. 151, n. 3, p. 473, doi. 10.1002/ijc.34033
- By:
- Publication type:
- Article
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 4, p. e245635, doi. 10.1001/jamanetworkopen.2024.5635
- By:
- Publication type:
- Article
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-72711-2
- By:
- Publication type:
- Article
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 7, p. 541, doi. 10.1007/s40261-024-01372-0
- By:
- Publication type:
- Article
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer.
- Published in:
- Biomedicines, 2024, v. 12, n. 4, p. 809, doi. 10.3390/biomedicines12040809
- By:
- Publication type:
- Article
Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day.
- Published in:
- Biomedicines, 2022, v. 10, n. 2, p. 411, doi. 10.3390/biomedicines10020411
- By:
- Publication type:
- Article
Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience.
- Published in:
- Diagnostics (2075-4418), 2022, v. 12, n. 3, p. 685, doi. 10.3390/diagnostics12030685
- By:
- Publication type:
- Article
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 Pandemic.
- Published in:
- Oncologist, 2022, v. 27, n. 8, p. e633, doi. 10.1093/oncolo/oyac071
- By:
- Publication type:
- Article
Beyond N staging in colorectal cancer: Current approaches and future perspectives.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.937114
- By:
- Publication type:
- Article
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS / BRAF Wild-Type mCRC Patients.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.940523
- By:
- Publication type:
- Article
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-022-02332-2
- By:
- Publication type:
- Article
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype
- Published in:
- Medical Oncology, 2021, v. 38, n. 3, p. 1, doi. 10.1007/s12032-021-01464-3
- By:
- Publication type:
- Article